Please turn JavaScript on
ProMIS Neurosciences, Inc. (PMN) Press Releases icon

ProMIS Neurosciences, Inc. (PMN) Press Releases

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.12 / day

Message History

TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix

License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs

Cam...


Read full story
PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data PMN310 binds selectively to toxic amyloid-beta oligomers, and its IgG1 backbone is designed to promote clearance of toxic oligomers Ivana Rubino, Ph.D., a s...

Read full story

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside ch...


Read full story
Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report...


Read full story